 Akari Therapeutics, Plc AKTX, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement C5 andor leukotriene LTB4 systems are implicated, today announced that the European Medicines Agency EMA has issued a positive opinion on Akaris application for orphan designation of nomacopan for the treatment of bullous pemphigoid BP. Akari recently announced the successful completion of a Phase II study in BP where the combined therapeutic role of both complement C5 and leukotriene LTB4 has been well documented. 